Department of Laboratory Medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan.
Biobank and Tissue Bank, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan; Department of Medical Research, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan.
Oral Oncol. 2021 Sep;120:105402. doi: 10.1016/j.oraloncology.2021.105402. Epub 2021 Jun 24.
OBJECTIVES: microRNA (miRNA) expression patterns have provided new insight as biomarkers of prognosis as well as novel therapeutic targets for several neoplasms. However, the role of exosomal miRNA in the prognosis of oral squamous cell carcinoma (OSCC) has not yet been completely clarified. Paired primary tumor and normal oral epithelial cells from OSCC patients were obtained, and the exosomal miRNA profiles between them were compared by miRNA microarray analysis. The miRNA levels in the serum exosomes of OSCC patients were verified by real-time quantitative reverse transcription PCR (qRT-PCR) analysis. Finally, the biological functions and the potential as a prognostic marker of the selected miRNA candidates were analyzed in the OSCC cells and patients, respectively. RESULTS: Exosomal miR-155 and miR-21 were significantly upregulated, and exosomal miR-126 was dramatically downregulated in the primary OSCC cells and the serum of OSCC patients. In the analysis of oncogenic behaviors, coculture with either miR-155-rich or miR-21-rich exosomes could promote cell proliferation and invasion accompanied with downregulation of PTEN and Bcl-6 tumor suppressors. Moreover, treatment with miR-126-rich exosomes inhibited oncogenic behaviors and oncogene EGFL7 expression in OSCC cells. Finally, exosomal miR-126 was reduced in the serum of the late-staged OSCC patients, and downregulation of blood exosomal miR-126 was associated with poor survival in OSCC patients. CONCLUSION: Exosomal miR-155 and miR-21 are oncogenic miRNAs which suppress PTEN and Bcl-6 expression, and exosomal miR-126 acts as a tumor suppressor which downregulates EGFL7 in OSCC. Furthermore, blood exosomal miRNAs may serve as biomarkers for the diagnosis and prognosis of OSCC.
目的:微小 RNA(miRNA)表达模式为多种肿瘤的预后提供了新的见解,并为新的治疗靶点提供了新的见解。然而,外泌体 miRNA 在口腔鳞状细胞癌(OSCC)预后中的作用尚未完全阐明。从 OSCC 患者中获得配对的原发性肿瘤和正常口腔上皮细胞,并通过 miRNA 微阵列分析比较它们之间的外泌体 miRNA 谱。通过实时定量逆转录 PCR(qRT-PCR)分析验证了 OSCC 患者血清外泌体中的 miRNA 水平。最后,分别在 OSCC 细胞和患者中分析了选定 miRNA 候选物的生物学功能和作为预后标志物的潜力。
结果:原发性 OSCC 细胞和 OSCC 患者的血清中外泌体 miR-155 和 miR-21 显著上调,外泌体 miR-126 显著下调。在致癌行为分析中,与富含 miR-155 或 miR-21 的外泌体共培养可促进细胞增殖和侵袭,同时下调抑癌基因 PTEN 和 Bcl-6。此外,富含 miR-126 的外泌体处理可抑制 OSCC 细胞的致癌行为和癌基因 EGFL7 的表达。最后,晚期 OSCC 患者血清中外泌体 miR-126 减少,血液外泌体 miR-126 下调与 OSCC 患者的不良生存相关。
结论:外泌体 miR-155 和 miR-21 是致癌 miRNA,可抑制 PTEN 和 Bcl-6 的表达,外泌体 miR-126 作为肿瘤抑制因子,下调 OSCC 中的 EGFL7。此外,血液外泌体 miRNA 可能作为 OSCC 诊断和预后的生物标志物。
Biomed Pharmacother. 2019-11-5
J Oral Maxillofac Surg. 2022-12
Eur Rev Med Pharmacol Sci. 2019-1
Naunyn Schmiedebergs Arch Pharmacol. 2025-6-10
Bioact Mater. 2025-4-3
Int J Oral Sci. 2025-2-4
Clin Transl Oncol. 2025-1
Int J Oral Sci. 2024-1-15
Aging (Albany NY). 2023-11-16
Zhejiang Da Xue Xue Bao Yi Xue Ban. 2023-8-25
Cancers (Basel). 2023-7-25